SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · Teva priced a ~$4.9B multi-tranche senior notes offering across five…

Teva Pharmaceutical Industries Ltd · PRESS-RELEASE filed Sep 10, 2026 at 06:04 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Sep 10, 2026 at 06:04 ET

Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the conditional redemption of up to ~$4.5B in higher-coupon debt (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This liability management refinancing reduces near-term interest costs and extends maturities, a credit-positive move for bondholders but neutral for equity holders as it does not alter the fundamental business outlook or leverage trajectory beyond the refinancing math. The cross-filing 424B5 from 2 days ago previewed this offering; the pricing confirmation removes uncertainty on size and coupon rates, with settlement expected September 16, 2026.

  • Offering sized at ~$4.9B equivalent across five tranches: €1B 4.250% 2033, €500M 4.625% 2036, $1B 5.500% 2034, $1B 5.750% 2037, $1.2B 5.250% 2032.
  • Proceeds to fund conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, 4.750% 2027s, 4.375% 2030s).
  • Additional notice to redeem all 8.125% 2031 notes and reduce 4.375% 2030 redemption from €1.25B to €1.15B expected on Sept 10, 2026.
  • Settlement expected on or about September 16, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access